GLP-1 Body Composition: Fat Loss, Muscle, and Visceral Fat Changes
Scale Weight Is Only Part of the Story
You step on the scale and see a number drop. That is good. But the number alone does not tell you what is actually changing in your body. You might be losing mostly fat. Or you might be losing a mix of fat and lean muscle tissue. Or you might be seeing mostly water loss. These differences matter for how you look, how strong you feel, and your long-term metabolic health.
GLP-1 medications do something specific to body composition that is worth understanding: most of the weight lost in trials was fat, and within fat mass, visceral fat (the internal fat around organs) fell proportionally more than total fat. That matters independent of what the scale says.
Here is what the research shows about body composition changes on GLP-1, and how to protect your lean mass along the way.
Fat Mass vs. Lean Mass: The 70-30 Split
When you lose weight on GLP-1, not all of it is fat. The best data comes from body composition substudies of the STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) trials, which used DEXA scans on a subset of participants:
- SURMOUNT-1 (tirzepatide, 72 weeks, 160 participants): body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9%. About 75% of the weight lost was fat and about 25% was lean mass, in both the tirzepatide and placebo groups.[2]
- STEP 1 (semaglutide, 68 weeks, 140 participants): body weight fell 15.0%, fat mass 19.3%, and lean mass 9.7%. Because people start with more lean mass than fat mass, that works out to lean mass making up roughly a third or more of the weight lost. The proportion of lean mass relative to total body mass still went up.[3]
So “70-30” is a rough midpoint, not a fixed rule. A 2024 review found that lean mass ranged from about 15% or less to 40-60% of total weight lost across GLP-1 studies, and noted that “lean mass” includes organs, bone, and water, not only muscle.[4] These are trial averages; results vary.
This lean mass loss might sound alarming, but it helps to put it in context. Lean mass loss also happens with calorie restriction and with surgical weight loss. It is an expected part of creating a sustained calorie deficit: your body mobilizes both fat and some lean tissue when energy demand exceeds intake.
Resistance training and adequate protein intake are the main tools for protecting lean mass during weight loss. The evidence for these habits comes mostly from weight loss research in general; trials testing them specifically alongside GLP-1 medications are still limited.
This is not a limitation unique to the medication. It is how physiology works, and it is one of the main reasons strength training and nutrition guidance are worth building into your plan from the start, whether on your own, with a registered dietitian, or through a program that includes them.
Visceral Fat vs. Subcutaneous Fat: Which One Really Matters
Not all fat is created equal. Your body stores fat in two main locations: under your skin (subcutaneous fat) and around your internal organs (visceral fat). The difference is not cosmetic. It is metabolic.
Visceral fat is metabolically active and inflammatory. It secretes hormones and cytokines that impair insulin signaling, increase inflammation, and contribute to metabolic disease. High visceral fat is more strongly associated with insulin resistance, type 2 diabetes, cardiovascular disease, fatty liver disease, and metabolic syndrome than subcutaneous fat, even after accounting for total body weight.[5]
Subcutaneous fat is more metabolically neutral. It is the fat you can pinch. It does not directly impair insulin signaling in the same way.
Here is what stands out about GLP-1 medications: in the STEP 1 body composition substudy, regional visceral fat fell by 27.4% with semaglutide, compared with a 19.3% drop in total fat mass.[3] Waist circumference, a practical stand-in for visceral fat, also fell more than with placebo in STEP 1 and SURMOUNT-1.[1][2]
This is important because it suggests the metabolic effect of GLP-1 treatment extends beyond simple weight loss. Visceral fat is the type most strongly linked to metabolic disease, cardiovascular risk, and liver disease.
Measuring Body Composition: Beyond the Scale
The scale measures weight, not body composition. For example, if a person loses 20 pounds on GLP-1 and gains 5 pounds of muscle through resistance training, the scale might show only a 15-pound loss, even though their body composition improved (lost more fat, kept more muscle). This is why some people plateau on the scale while continuing to see visible body changes and feel stronger.
There are several ways to measure body composition. They vary in cost, accuracy, and accessibility.
DEXA Scan: The Gold Standard
A DEXA (dual-energy X-ray absorptiometry) scan is the most accurate and commonly used measurement of body composition. It measures fat mass, lean mass, and bone mineral density with excellent precision. A DEXA scan takes about 10 minutes, involves minimal radiation exposure (less than a chest X-ray), and is not uncomfortable.
DEXA scans are not routine for people taking GLP-1 medications, but they are increasingly available at fitness centers, medical facilities, and university research labs. Some people get a baseline DEXA before starting treatment and a follow-up DEXA after 6 months or a year to track body composition changes. This provides objective data on whether resistance training and nutrition are protecting lean mass.
Cost varies by facility, and insurance often does not cover a DEXA for body composition tracking. Ask for the self-pay price before you book.
Waist Circumference: The Practical Proxy
Waist circumference is a simple, practical, and evidence-backed proxy for visceral fat. You measure the circumference of your waist at the level of the navel, consistently, ideally at the same time of day and under the same conditions (after voiding, before eating).
Clinical cutoffs are:
- Men: <40 inches is the target threshold
- Women: <35 inches is the target threshold
Waist circumference above these thresholds is associated with increased metabolic risk, independent of BMI. In trials, waist circumference fell on average with GLP-1 treatment. Tracking your waist circumference every 2-4 weeks gives you a simple, free data point on visceral fat change.
Bioelectrical Impedance (BIA)
Consumer body composition scales and handheld devices use bioelectrical impedance to estimate body composition. They send a small electrical current through your body and measure how quickly it travels (muscle conducts electricity faster than fat). The device then estimates fat mass and lean mass.
BIA is convenient and affordable, but accuracy varies. These devices are sensitive to hydration status, which changes throughout the day and with diet. If you use a BIA scale, measure yourself consistently (same time of day, same hydration state) to track trends rather than relying on absolute values.
BodPod: Air Displacement Plethysmography
A BodPod is a pod-shaped chamber that measures body composition via air displacement. It is less common than DEXA and can be harder to find, but it provides accurate measurements and does not involve radiation.
Timeline: When Do Body Composition Changes Show Up?
Body composition changes lag behind scale weight changes. This is important to understand, because it means your progress is not always visible or measurable right away.
Here is a general pattern. It is not a prediction for any individual, and results vary:
Weeks 1-4: You see scale weight loss, partly from fluid loss and reduced food volume in your digestive tract. Body composition changes are occurring but are not yet large enough to measure with consumer methods.
Weeks 4-12: Scale weight loss continues as you stay in a calorie deficit. Fat mass reduction becomes measurable. If you are not doing resistance training, you may lose more lean mass along with fat. Resistance training with adequate protein helps protect lean mass.
Months 3-6: Body composition changes often become visible. Clothes fit differently. Your waist circumference may decrease noticeably. Metabolic markers (blood glucose, triglycerides, liver enzymes) may improve, even if scale weight loss slows.
Months 6-12: Weight loss often slows. If you keep training, lean mass is better protected, and some people see measurements and strength keep improving while the scale moves less.
Body Recomposition: Can You Gain Muscle While Losing Fat?
A question many people ask: “Can I build muscle while on GLP-1?”
The honest answer is: probably not in the way you might be imagining.
Pure body recomposition (simultaneous, substantial fat loss and muscle gain) is possible but rare and difficult for most adults. It typically happens under specific conditions: untrained individuals with high body fat, who start resistance training, eat adequate protein, and are in a modest calorie deficit. In those early stages, the beginner gains some muscle while losing fat.
But for most people on GLP-1, the physiology is different. You are in a calorie deficit. Your body is in a catabolic state (breaking down tissue for energy). In this state, building significant new muscle is very difficult because muscle growth requires a surplus of amino acids and energy (an anabolic state).
This does not mean you cannot be strong or build strength. Resistance training while on GLP-1 can improve strength and muscle tone. But the primary goal is not to build new muscle mass, it is to preserve the lean mass you have. How much lean mass people lose varies widely between studies,[4] and resistance training and adequate protein are the habits most likely to keep that share on the lower end.
This is why strength training and nutrition guidance matter. A licensed provider can tell you whether resistance training and a higher protein intake are appropriate for your health, and a registered dietitian or certified trainer can help you put them into practice.
Optimizing Your Body Composition: Three Evidence-Based Interventions
If body composition matters to you (it affects metabolic health, strength, and how you feel), three things matter:
1. Resistance Training
Resistance training is the most effective single intervention for preserving lean mass during weight loss. Most of that evidence comes from weight loss research in general; studies testing resistance training specifically alongside GLP-1 medications are still limited.
You do not need to be a bodybuilder. 2-3 sessions per week of progressive resistance training (weights, resistance bands, bodyweight exercises) is enough to send a clear signal to your body to preserve muscle during a calorie deficit.
If you are new to strength training, ask a licensed provider whether it is safe for you, and consider a certified trainer or physical therapist to help you start at your current fitness level. Some telehealth programs include fitness guidance; ask what is included before you sign up.
Read more about resistance training on GLP-1
2. Adequate Protein Intake
Protein is the building block of muscle and the primary stimulus for muscle protein synthesis. During a calorie deficit on GLP-1, higher protein intake supports lean mass preservation.
A common recommendation is 1.2 to 1.6 grams of protein per kilogram of body weight per day if you are doing resistance training. For a 200-pound person, that is roughly 110-145 grams of protein per day.
GLP-1 medications reduce appetite, which can make it harder to eat enough protein. This is where the challenge lies. A registered dietitian can help you structure your meals to hit protein targets without feeling uncomfortably full.
Read more about high-protein diets on GLP-1
3. Consistency and Time
Body composition changes take time. You cannot optimize lean mass preservation in 4 weeks. The research on resistance training and lean mass preservation involves 12-24 week intervention periods. If you want to see measurable improvements in body composition, plan on 3-6 months of consistent resistance training and nutrition.
Visceral Fat Reduction and Cardiovascular Health
The visceral fat reduction seen with GLP-1 medications may have cardiovascular and metabolic significance beyond simple weight loss.[5]
The SELECT trial, published in the New England Journal of Medicine in 2023, randomized 17,604 adults aged 45 and older with overweight or obesity and established cardiovascular disease, but without diabetes, to receive either semaglutide 2.4 mg or placebo. Major cardiovascular events (death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke) occurred in 6.5% of the semaglutide group and 8.0% of the placebo group, a 20% relative reduction.[6]
Was this reduction solely due to weight loss? Probably not. A prespecified analysis of SELECT found the benefit was consistent across baseline body weight and was not linked to how much weight people lost by week 20. Reduction in waist circumference accounted for an estimated 33% of the benefit, which suggests other mechanisms are also involved.[7]
This matters because it means the effect of GLP-1 treatment is not just about how you look. It reaches into metabolic and cardiovascular risk in ways the scale does not capture.
Read more about GLP-1 and cardiovascular health
Waist-to-Height Ratio: A Simple Health Marker
Beyond waist circumference, waist-to-height ratio is a simple marker of metabolic health. You divide your waist circumference by your height (both in the same units). A waist-to-height ratio of <0.5 is associated with low metabolic risk. A ratio >0.6 is associated with significantly increased risk.
Because waist circumference fell on average with GLP-1 treatment in trials, waist-to-height ratio tends to improve as well.
You can track this at home with a measuring tape and calculator. No expensive equipment needed.
The Bottom Line: What Body Composition Data Actually Shows
Here is what the research shows so far:
Most weight lost on GLP-1 in trials was fat mass. About 75% fat and 25% lean mass in the SURMOUNT-1 substudy; lean mass made up roughly a third or more in the STEP 1 substudy. Some lean mass loss is normal and expected.
Resistance training and adequate protein may help protect lean mass. The evidence comes mostly from weight loss research in general.
GLP-1 medications appear to reduce visceral fat proportionally more than total fat, and visceral fat is the type most strongly linked to metabolic disease and cardiovascular risk.
Waist circumference is a practical, free proxy for visceral fat reduction. Track it consistently to see the changes that the scale might not capture.
Body composition changes take time. Plan for 3-6 months of consistent training and nutrition to see significant improvements.
The metabolic effect of visceral fat reduction extends beyond weight loss. Lower visceral fat is associated with improvements in blood pressure, lipid profiles, and inflammation markers.
If you have been frustrated by scale weight that does not move while your body composition is improving, or if you want to know exactly what is happening to your fat and lean mass during treatment, a DEXA scan provides objective data. But tracking waist circumference, how your clothes fit, and your strength in the gym are free, practical ways to measure progress.
A licensed provider can help you decide what is right for your health, and a registered dietitian or certified trainer can help with nutrition and strength work. If you are comparing programs, ask whether nutrition and fitness guidance is included or costs extra.
Track Your Body Composition
Consider these practical tracking methods over the next 12 weeks:
- Waist circumference: Measure every 2-4 weeks. Target <40 inches (men) or <35 inches (women).
- How your clothes fit: Try on the same pair of jeans or a specific piece of clothing every 4 weeks.
- Strength in the gym: Track weights lifted or reps completed. Progressive improvement signals lean mass preservation.
- Progress photos: Take them in the same lighting, same pose, every 8 weeks. Visual changes are often clearer than measurements.
- DEXA scan (optional): Baseline before starting, then 6-12 months into treatment. Provides precise fat mass, lean mass, and bone density data.
The goal is not just to see a number on the scale. The goal is to lose fat, preserve muscle, improve your waist circumference and visceral fat, and build a body that is stronger and metabolically healthier.
That is what body composition optimization looks like.
Citations
[1] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
[2] Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. https://pubmed.ncbi.nlm.nih.gov/39996356/ (Main trial: Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/)
[3] Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Supplement_1):A16. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
[4] Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. https://pubmed.ncbi.nlm.nih.gov/38937282/
[5] Cesaro A, De Michele G, Fimiani F, et al. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options. Front Cardiovasc Med. 2023;10:1187735. https://pubmed.ncbi.nlm.nih.gov/37576108/
[6] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
[7] Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257-2268. https://pubmed.ncbi.nlm.nih.gov/41138739/
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation, and never start, stop, or change a medication without guidance from your prescriber. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products; they may differ in formulation, purity, and potency. Results vary. Trial results describe study participants and are not a prediction for any individual.